Key facts
- This page summarizes Shubh Goel's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Dec 2021, 16:49.
Shubh Goel - 20 Dec 2021 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- FENC
- Reported as of
- 20 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Dec 2021, 16:49:15 UTC
- Prior SEC filing
- 03 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shubh Goel, Chief Commercial Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Shubh Goel filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 20 Dec 2021.
Change
- Previous filing in this sequence was filed on 03 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FENC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 20 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 75,000
- Exercise price
- $4.08
- Footnotes
- F1, F3
FENC
transaction
Derivative
Restricted Share Unit (right to receive value of a share)
Award
- Transaction value
- $0
- Shares
- +37,500
- Change %
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 20 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 37,500
- Exercise price
- $0.000000
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On December 20, 2021, Shubh Goel was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
Footnote F2
On December 20, 2021, Shubh Goel was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
Footnote F3
Item vests 100% upon FDA approval of PEDMARKTM.